10times
Conference

Viral Safety by Design for Cell and Gene Therapy Products

16 Oct 2020

About Followers Reviews Exhibitors Photos Speakers 1

Together with product efficacy, product safety is an essential characteristic of any medicinal product including cell and gene therapy (C&GT) biologics. Adventitious agents (viruses, bacteria, mycoplasma, prions, etc) pose constant risk to these biologics, and, as such they may impact directly product and patient safety. It is therefore of supreme importance to intentionally (by design) employ effective measures across the whole C&GT product manufacturing process to mitigate risk of adventitious agents. This presentation will review various interconnected steps throughout the manufacturing process, from the raw materials to the fill and finish, that would, in concert, help mitigate the risk while providing a high degree of product safety by design.


Timings

09:00 AM-06:00 PM (expected)
Not Verified

Entry Fees

Check Official Website

Participants

upto 100
Delegates
Estimated Count

Category & Type

Conference
Industrial Engineering

Editions

16 Oct 2020 Interested


Frequency Newly Listed

Official Links

WebsiteContacts


Report Error
Claim this event

Organizer

Logo Reserve a Slot

BIOPHARMA ASIA MAGAZINE

South Korea 50 Total Events / 36 Upcoming Events

Schedule & Agenda

Fri, 16 Oct 05:30 AM - 05:30 AM Session
Online Webcast

Speakers

Speaker
Mark Plavsic

Mark Plavsic

Chief Technology Officer at Lysogene

More Events From The Organizer